Loading patent…
AssigneeKorea Research Institute of Bioscience and Biotechnology
InventorsMisun Won, Kyung-Sook Chung, Young Joo Kim, Hye Kyung Hong, Young Il Yeom, Chae Ok Yun, Yu-Kyoung Oh, Kyung Bin Song, Hee Gu Lee, Eun Young Song, Young Ho Kim, Moon Hee Kim, Kyeong-Eun Jung
Estimating the term…
The present invention provides a pharmaceutical composition for treating cancer, comprising at least one selected from deoxyribonucleic acids (DNA) for encoding small interfering RNA (siRNA) which complementarily binds to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, represented by sequence number 3, sequence number 5, and sequence number 7 to inhibit the intracellular expression of the FLJ25416 gene, antisense RNA which inhibits expression of the FLJ25416 gene, and short hairpin RNA (shRNA) which inhibits expression of the FLJ25416 gene. As the siRNA, which is complementary to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, the antisense RNA, and the shRNA, according to the present invention, inhibit expression of the FLJ25416 gene which is known to be expressed in cancer cells, and thus kill cancer cells, the composition of the present invention can be used as a novel anti-cancer agent.
A pharmaceutical composition for therapy of cancer, comprising a nucleic acid molecule, wherein the nucleic acid molecule is:
A pharmaceutical composition, comprising a retrovirus, wherein the retrovirus comprises RNA whose ribonucleotide sequence is complementary to the base sequence of an FLJ25416 transcript (mRNA) set forth as SEQ ID NO:
A nucleic acid molecule selected from among:
A retrovirus, comprising RNA, whose ribonucleotide sequence is complementary to the base sequence of the FLJ25416 transcript (mRNA) set forth in SEQ ID NO:
A method for treating cancer, comprising delivering an shRNA molecule to a subject, wherein:
Dependencies are inferred from the claim text.